These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 932970)
1. In vivo and in vitro evaluation of a microencapsulated narcotic antagonist. Mason N; Thies C; Cicero TJ J Pharm Sci; 1976 Jun; 65(6):847-50. PubMed ID: 932970 [TBL] [Abstract][Full Text] [Related]
2. Long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites. Yolles S; Leafe TD; Woodland JH; Meyer FJ J Pharm Sci; 1975 Feb; 64(2):348-9. PubMed ID: 1127596 [TBL] [Abstract][Full Text] [Related]
3. Development of injectable microcapsules for use in the treatment of narcotic addiction. Thies C Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):19-20. PubMed ID: 967230 [TBL] [Abstract][Full Text] [Related]
4. Sustained administration of cyclazocine for antagonism of morphine. Sullivan MF; Ruemmler PS; Kalkwarf DR Drug Alcohol Depend; 1976 Oct; 1(6):415-28. PubMed ID: 1035154 [TBL] [Abstract][Full Text] [Related]
5. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. Pircio AW; Gylys JA J Pharmacol Exp Ther; 1975 Apr; 193(1):23-34. PubMed ID: 237112 [TBL] [Abstract][Full Text] [Related]
6. Development of injectable microcapsules for use in the treatment of narcotic addiction. Thies C Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):19-20. PubMed ID: 1241971 [TBL] [Abstract][Full Text] [Related]
7. Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. O'Callaghan JP; Holtzman SG J Pharmacol Exp Ther; 1975 Mar; 192(3):497-505. PubMed ID: 1168252 [TBL] [Abstract][Full Text] [Related]
8. Behavioral and morphine-antagonist effects of the optical isomers of pentazocine and cyclazocine. McMillan DE; Harris LS J Pharmacol Exp Ther; 1972 Mar; 180(3):269-79. PubMed ID: 5012778 [No Abstract] [Full Text] [Related]
9. Long-acting delivery systems for narcotic antagonists. 1. Woodland JH; Yolles S; Blake DA; Helrich M; Meyer FJ J Med Chem; 1973 Aug; 16(8):897-901. PubMed ID: 4745832 [No Abstract] [Full Text] [Related]
11. Dissociation of the opioid and nonopioid effects of cyclazocine. Calligaro D; Young GA; Khazan N Pharmacol Biochem Behav; 1988 May; 30(1):163-7. PubMed ID: 3174740 [TBL] [Abstract][Full Text] [Related]
12. Quantitative studies on the antagonism by naloxone of some narcotic and narcotic-antagonist analgesics. Smits SE; Takemori AE Br J Pharmacol; 1970 Jul; 39(3):627-38. PubMed ID: 5472208 [TBL] [Abstract][Full Text] [Related]
13. The discriminative stimulus properties of cyclazocine: generalization studies involving nalorphine, morphine and LSD. Rosecrans JA; Chance WT; Spencer RM Res Commun Chem Pathol Pharmacol; 1978 May; 20(2):221-37. PubMed ID: 674812 [TBL] [Abstract][Full Text] [Related]
14. Further characterization of the three-choice morphine, cyclazocine and saline discrimination paradigm: opioids with agonist and antagonist properties. White JM; Holtzman SG J Pharmacol Exp Ther; 1983 Jan; 224(1):95-9. PubMed ID: 6336785 [TBL] [Abstract][Full Text] [Related]
15. Biocompatible implants for the sustained zero-order release of narcotic antagonists. Abrahams RA; Ronel SH J Biomed Mater Res; 1975 May; 9(3):355-66. PubMed ID: 1176491 [TBL] [Abstract][Full Text] [Related]
16. Naltrexone microspheres: in vitro release and effect on morphine analgesia in mice. He GA; Hou HM; Liu XJ Acta Pharmacol Sin; 2001 Jun; 22(6):530-3. PubMed ID: 11747760 [TBL] [Abstract][Full Text] [Related]